Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors

• Status: Completed
• Trial end date: 2020-05-14
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-001 in Subjects with Metastatic or Locally-advanced Solid Tumors

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ImmuneOncia Therapeutics Inc.

Criteria

Inclusion Criteria:

1. Signed Informed Consent Form (ICF).

2. Adult (19 years or older).

3. Histologically or cytologically proven metastatic or locally-advanced solid tumors

Exclusion Criteria:

1. Treatment with non-permitted drugs (within the past 28 days of Screening), including but not limited to systemic immunosuppressive agents, any other investigational medicinal product (IMP), anti-coagulant, or live vaccines.

2. Any prior cancer immunotherapy

3. Concurrent anticancer treatments